Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment
Authors:
- Chen-Jee HongCHChen-Jee Hong
- Ying-Jay LiouYLYing-Jay Liou
- Ya Mei BaiYBYa Mei Bai
- Shih-Jen TsaiShih-Jen Tsai
- 1 June 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 20 (6) , 359-366
Abstract
Objective Schizophrenic patients treated with atypical antipsychotics (AAPs) often develop excessive body weight gain (BWG), which may lead to further morbidity and poor treatment compliance. This study examined whether genetic variants in the dopamine receptor D2 (DRD2) gene may be associated with body weight change after AAP treatment. Methods The study included 479 schizophrenic patients treated with clozapine (n=239), olanzapine (n=70) or risperidone (n=170) for an average of 48.2±27.8 months. BWG was defined as an increase of more than 7% of the baseline body weight during AAP treatment. Thirteen common single nucleotide polymorphisms of the DRD2 gene were chosen as tagging single nucleotide polymorphisms. Results In single-marker-based analysis, the DRD2 rs4436578-C homozygous genotype was found to be associated with a significantly increased risk of BWG [P=0.001, adjusted odds ratio=3.36 (95% confidence interval=1.62∼7.00)]. In addition, haplotype analysis further showed that the rs4436578-C-allele-related haplotype was more frequent in those patients with BWG than those without (P=0.01∼0.00019). Conclusion Our findings confirm the importance of genetic factors in body weight change induced by long-term AAP treatment in patients with schizophrenia and indicate a role of DRD2 in body weight regulation during long-term AAP treatment.Keywords
This publication has 39 references indexed in Scilit:
- D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetesNutrition, 2009
- Likelihood-Based Association Analysis for Nuclear Families and Unrelated Subjects with Missing Genotype DataHuman Heredity, 2008
- Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairsPsychiatric Genetics, 2005
- A Direct Approach to False Discovery RatesJournal of the Royal Statistical Society Series B: Statistical Methodology, 2002
- Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in ratsJournal of Biomedical Science, 2002
- Bodyweight Gain Associated with Atypical AntipsychoticsCNS Drugs, 2001
- Bodyweight Gain with Atypical AntipsychoticsDrug Safety, 2001
- Association of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes mellitus in Pima IndiansInternational Journal of Obesity, 2000
- Dopaminergic Agonists Normalize Elevated Hypothalamic Neuropeptide Y and Corticotropin-Releasing Hormone, Body Weight Gain, and Hyperglycemia in ob/ob MiceNeuroendocrinology, 2000
- The Dopamine D2 Receptor (DRD2) as a Major Gene in Obesity and HeightBiochemical Medicine and Metabolic Biology, 1993